Whereas ARBs and ACEI have demonstrated their efficiency in improving insulin sensitivity and reducing end-organ damage and are now often considered as first-line therapy in hypertension with metabolic syndrome or diabetes [3], [4], [5], [30], association of anti-oxidants or anti-nitrants in an attempt to further reduce deleterious nitrative stress might be worth considering in severely affected or non-responsive patients. This evidence concerns the gene INS and metabolic syndrome.